Methods for Investigating VLA-4 (CD49d/CD29) Expression and Activation in Chronic Lymphocytic Leukemia and Its Clinical Applications

Antonella Zucchetto, Erika Tissino, Alexander Chigaev, Tanja Nicole Hartmann, Valter Gattei

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The integrin heterodimer CD49d/CD29 (a.k.a. Very Late Antigen-4, VLA-4) mediates cell-cell and cell-matrix interaction through the binding of its ligands VCAM-1 and fibronectin. VLA-4 can be present on the cell surface at different conformation states that affect the binding affinity for the ligands. In chronic lymphocytic leukemia (CLL), higher VLA-4 levels, as determined by measuring the expression of CD49d chain by flow cytometry, have been demonstrated to associate with a worse prognosis, in keeping with the role of VLA-4 as key molecule favoring CLL cell localization in protective niches of bone marrow and lymph nodes. Given the emerging clinical relevance of VLA-4 evaluation in CLL, both in the setting of the conventional chemo-immunotherapy and the novel drugs targeting the BCR pathway, here we describe the flow cytometric approaches followed by us to quantify the CD49d expression levels and the VLA-4 activation status in CLL cells.

Original languageEnglish
Title of host publicationMethods in Molecular Biology
PublisherHumana Press Inc.
Pages101-112
Number of pages12
DOIs
Publication statusPublished - Jan 1 2019

Publication series

NameMethods in Molecular Biology
Volume1881
ISSN (Print)1064-3745

Fingerprint

Integrin alpha4beta1
B-Cell Chronic Lymphocytic Leukemia
Ligands
Vascular Cell Adhesion Molecule-1
Drug Delivery Systems
Fibronectins
Integrins
Cell Communication
Immunotherapy
Flow Cytometry
Lymph Nodes
Bone Marrow

Keywords

  • CD49d expression
  • Flow cytometry
  • HUTS-21 antibody
  • Integrin
  • VLA-4 activation

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics

Cite this

Zucchetto, A., Tissino, E., Chigaev, A., Hartmann, T. N., & Gattei, V. (2019). Methods for Investigating VLA-4 (CD49d/CD29) Expression and Activation in Chronic Lymphocytic Leukemia and Its Clinical Applications. In Methods in Molecular Biology (pp. 101-112). (Methods in Molecular Biology; Vol. 1881). Humana Press Inc.. https://doi.org/10.1007/978-1-4939-8876-1_8

Methods for Investigating VLA-4 (CD49d/CD29) Expression and Activation in Chronic Lymphocytic Leukemia and Its Clinical Applications. / Zucchetto, Antonella; Tissino, Erika; Chigaev, Alexander; Hartmann, Tanja Nicole; Gattei, Valter.

Methods in Molecular Biology. Humana Press Inc., 2019. p. 101-112 (Methods in Molecular Biology; Vol. 1881).

Research output: Chapter in Book/Report/Conference proceedingChapter

Zucchetto, A, Tissino, E, Chigaev, A, Hartmann, TN & Gattei, V 2019, Methods for Investigating VLA-4 (CD49d/CD29) Expression and Activation in Chronic Lymphocytic Leukemia and Its Clinical Applications. in Methods in Molecular Biology. Methods in Molecular Biology, vol. 1881, Humana Press Inc., pp. 101-112. https://doi.org/10.1007/978-1-4939-8876-1_8
Zucchetto, Antonella ; Tissino, Erika ; Chigaev, Alexander ; Hartmann, Tanja Nicole ; Gattei, Valter. / Methods for Investigating VLA-4 (CD49d/CD29) Expression and Activation in Chronic Lymphocytic Leukemia and Its Clinical Applications. Methods in Molecular Biology. Humana Press Inc., 2019. pp. 101-112 (Methods in Molecular Biology).
@inbook{c47c7d45c6834b92ab52e9a93f626042,
title = "Methods for Investigating VLA-4 (CD49d/CD29) Expression and Activation in Chronic Lymphocytic Leukemia and Its Clinical Applications",
abstract = "The integrin heterodimer CD49d/CD29 (a.k.a. Very Late Antigen-4, VLA-4) mediates cell-cell and cell-matrix interaction through the binding of its ligands VCAM-1 and fibronectin. VLA-4 can be present on the cell surface at different conformation states that affect the binding affinity for the ligands. In chronic lymphocytic leukemia (CLL), higher VLA-4 levels, as determined by measuring the expression of CD49d chain by flow cytometry, have been demonstrated to associate with a worse prognosis, in keeping with the role of VLA-4 as key molecule favoring CLL cell localization in protective niches of bone marrow and lymph nodes. Given the emerging clinical relevance of VLA-4 evaluation in CLL, both in the setting of the conventional chemo-immunotherapy and the novel drugs targeting the BCR pathway, here we describe the flow cytometric approaches followed by us to quantify the CD49d expression levels and the VLA-4 activation status in CLL cells.",
keywords = "CD49d expression, Flow cytometry, HUTS-21 antibody, Integrin, VLA-4 activation",
author = "Antonella Zucchetto and Erika Tissino and Alexander Chigaev and Hartmann, {Tanja Nicole} and Valter Gattei",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/978-1-4939-8876-1_8",
language = "English",
series = "Methods in Molecular Biology",
publisher = "Humana Press Inc.",
pages = "101--112",
booktitle = "Methods in Molecular Biology",

}

TY - CHAP

T1 - Methods for Investigating VLA-4 (CD49d/CD29) Expression and Activation in Chronic Lymphocytic Leukemia and Its Clinical Applications

AU - Zucchetto, Antonella

AU - Tissino, Erika

AU - Chigaev, Alexander

AU - Hartmann, Tanja Nicole

AU - Gattei, Valter

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The integrin heterodimer CD49d/CD29 (a.k.a. Very Late Antigen-4, VLA-4) mediates cell-cell and cell-matrix interaction through the binding of its ligands VCAM-1 and fibronectin. VLA-4 can be present on the cell surface at different conformation states that affect the binding affinity for the ligands. In chronic lymphocytic leukemia (CLL), higher VLA-4 levels, as determined by measuring the expression of CD49d chain by flow cytometry, have been demonstrated to associate with a worse prognosis, in keeping with the role of VLA-4 as key molecule favoring CLL cell localization in protective niches of bone marrow and lymph nodes. Given the emerging clinical relevance of VLA-4 evaluation in CLL, both in the setting of the conventional chemo-immunotherapy and the novel drugs targeting the BCR pathway, here we describe the flow cytometric approaches followed by us to quantify the CD49d expression levels and the VLA-4 activation status in CLL cells.

AB - The integrin heterodimer CD49d/CD29 (a.k.a. Very Late Antigen-4, VLA-4) mediates cell-cell and cell-matrix interaction through the binding of its ligands VCAM-1 and fibronectin. VLA-4 can be present on the cell surface at different conformation states that affect the binding affinity for the ligands. In chronic lymphocytic leukemia (CLL), higher VLA-4 levels, as determined by measuring the expression of CD49d chain by flow cytometry, have been demonstrated to associate with a worse prognosis, in keeping with the role of VLA-4 as key molecule favoring CLL cell localization in protective niches of bone marrow and lymph nodes. Given the emerging clinical relevance of VLA-4 evaluation in CLL, both in the setting of the conventional chemo-immunotherapy and the novel drugs targeting the BCR pathway, here we describe the flow cytometric approaches followed by us to quantify the CD49d expression levels and the VLA-4 activation status in CLL cells.

KW - CD49d expression

KW - Flow cytometry

KW - HUTS-21 antibody

KW - Integrin

KW - VLA-4 activation

UR - http://www.scopus.com/inward/record.url?scp=85055146331&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055146331&partnerID=8YFLogxK

U2 - 10.1007/978-1-4939-8876-1_8

DO - 10.1007/978-1-4939-8876-1_8

M3 - Chapter

T3 - Methods in Molecular Biology

SP - 101

EP - 112

BT - Methods in Molecular Biology

PB - Humana Press Inc.

ER -